dc.creator | Rosado Sánchez, Isaac | es |
dc.creator | Herrero Fernández, Inés | es |
dc.creator | Genebat González, Miguel | es |
dc.creator | Romero, Jorge Del | es |
dc.creator | Riera, Melchor | es |
dc.creator | Podzamczer, Daniel | es |
dc.creator | Olalla, Julián | es |
dc.creator | Vidal, Francesc | es |
dc.creator | Muñoz-Fernández, Mª Angeles | es |
dc.creator | Leal Noval, Manuel | es |
dc.creator | Pacheco López, Yolanda María | es |
dc.date.accessioned | 2018-08-20T10:40:51Z | |
dc.date.available | 2018-08-20T10:40:51Z | |
dc.date.issued | 2018-07-18 | |
dc.identifier.citation | Rosado Sánchez, I., Herrero-Fernández, I., Genebat González, M., Romero, J.D., Riera, M., Podzamczer, D.,...,Pacheco López, Y.M. (2018). HIV-Infected Subjects With Poor CD4 T-Cell Recovery Despite Effective Therapy Express High Levels of OX40 and α4β7 on CD4 T-Cells Prior Therapy Initiation. Frontiers in Immunology, 9, 1673-1-1673-6. | |
dc.identifier.issn | 1664-3224 | es |
dc.identifier.uri | https://hdl.handle.net/11441/78186 | |
dc.description.abstract | Background
HIV-infected subjects with suboptimal CD4 restoration despite suppressive combined antiretroviral treatment (cART) (immunodiscordant subjects) have been classically characterized after a variable period of time under cART. Recently, we have reported that an increased frequency of proliferating CD4 T-cells in these subjects is already present before the cART onset. The potential contribution of peripheral compensatory homeostatic proliferation (HP) is yet unknown. We aimed to analyze the expression of HP-related cellular markers on CD4 T-cells of immunodiscordant subjects before cART.
Go to:
Methods
We analyzed the expression of OX40 and α4β7 on peripheral CD4 T-cells from immunodiscordant and control subjects (n = 21 each group) before cART initiation, and also on available follow-up samples (after 24 month of suppressive cART). Additionally, we tested the expression of these markers in an in vitro system for the study of human HP processes.
Go to:
Results
Immunodiscordant subjects showed increased levels of OX40 and α4β7 on CD4 T-cells before cART initiation. While the cART tended to reduce these levels, immunodiscordant subjects still maintained comparatively higher levels of OX40 and α4β7 after 24 months under suppressive cART. These HP-related markers were upregulated in vitro during the human HP, especially during the fast HP.
Go to:
Conclusion
Our results are compatible with exacerbated HP processes in immunodiscordant subjects, already before the cART onset. | es |
dc.description.sponsorship | Fondo de Investigación Sanitaria FIS PI14/01693 PI13/0796 PI16/0503 | es |
dc.description.sponsorship | Fondos Europeos para el Desarrollo Regional (FEDER) CTS2593 | es |
dc.description.sponsorship | Junta de Andalucía. Consejería de Economía, Innovación, Ciencia y Empleo CTS2593 | es |
dc.description.sponsorship | AGAUR 2017SGR948 | es |
dc.description.sponsorship | GILEAD GLD14/293 | es |
dc.description.sponsorship | The Spanish AIDS Research Network of Excellence RD12/0017/0029 RD16/0025/0019 RD16/0025/0006 | es |
dc.description.sponsorship | Junta de Andalucía. Consejería de Salud y Bienestar Social C-0013-2017 | es |
dc.format | application/pdf | es |
dc.language.iso | eng | es |
dc.publisher | International Union of Immunological Societies | es |
dc.relation.ispartof | Frontiers in Immunology, 9, 1673-1-1673-6. | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Immunodiscordant response to combined antiretroviral treatment | es |
dc.subject | Low CD4 recovery | es |
dc.subject | Homeostatic parameters | es |
dc.subject | Homeostatic proliferation | es |
dc.subject | OX40 | es |
dc.subject | α4β7 | es |
dc.subject | CD4 T-cell homeostasis | es |
dc.subject | HIV | es |
dc.title | HIV-Infected Subjects With Poor CD4 T-Cell Recovery Despite Effective Therapy Express High Levels of OX40 and α4β7 on CD4 T-Cells Prior Therapy Initiation | es |
dc.type | info:eu-repo/semantics/article | es |
dcterms.identifier | https://ror.org/03yxnpp24 | |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Instituto de Biomedicina de Sevilla (IBIS) | es |
dc.relation.projectID | FIS | es |
dc.relation.projectID | PI14/01693 | es |
dc.relation.projectID | PI13/0796 PI16/0503 | es |
dc.relation.projectID | CTS2593 | es |
dc.relation.projectID | 2017SGR948 | es |
dc.relation.projectID | GLD14/293 | es |
dc.relation.projectID | RD12/0017/0029 | es |
dc.relation.projectID | RD16/0025/0019 | es |
dc.relation.projectID | RD16/0025/0006 | es |
dc.relation.projectID | C-0013-2017 | es |
dc.relation.publisherversion | https://doi.org/10.3389/fimmu.2018.01673 | es |
dc.identifier.doi | 10.3389/fimmu.2018.01673 | es |
idus.format.extent | 6 p. | es |
dc.journaltitle | Frontiers in Immunology | es |
dc.publication.volumen | 9 | es |
dc.publication.initialPage | 1673-1 | es |
dc.publication.endPage | 1673-6 | es |